Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Afatinib improves OS in lung cancer trial
July 2015
SHARING OPTIONS:

RIDGEFIELD, Conn.—In Boehringer Ingelheim's recent LUX-Lung 8 trial, which compared the safety and efficacy of afatinib and erlotinib in patients with advanced squamous cell carcinoma of the lung progressing after treatment with first-line chemotherapy, afatinib treatment extended survival to a median of 7.9 months compared to 6.8 months with erlotinib. After one year, 36.4 percent of patients treated with afatinib were still alive, compared to 28.2 percent treated with erlotinib. The primary endpoint of progression-free survival was met, as afatinib treatment reduced the risk of cancer progression by 19 percent compared to erlotinib, and a higher proportion of patients treated with afatinib reported improvement in cough, shortness of breath and overall well-being compared with those treated with erlotinib.
 
“With these positive overall survival results, we will pursue global regulatory submissions for the treatment of afatinib in patients with squamous cell carcinoma of the lung,” said Dr. Tunde Otulana, senior vice president, Clinical Development and Medical Affairs, Boehringer Ingelheim.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.